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Abstract Angiopoietin-like protein 4 (ANGPTL4) has
been reported to promote tumor growth, metastasis, and
angiogenesis under certain conditions. The aim of this
study was to examine ANGPTL4 expression in tumor and
serum tissues from esophageal squamous cell carcinoma
(ESCC) patients. A total of 78 ESCC patients treated with
radical resection were enrolled in this study. Immunohis-
tochemistry was used to detect ANGPTL4 expression in
ESCC tissues. Serum ANGPTL4 levels were determined
via enzyme-linked immunosorbent assay (ELISA). The
receiver operating characteristics curve was constructed to
describe diagnostic specificity and sensitivity. There were
52 cases (69.2 %) showing a higher level of ANGPTL4
expression in tumor tissues than that in normal tissues, and
the rate of ANGPTL4 protein high/moderate expression in
ESCC and normal tissues was 55.1 % (43/78) and 6.4 %
(5/78), respectively, with a significant difference
(P \ 0.001). Moreover, the high/moderate of ANGPTL4
protein was significantly associated with lymph metastasis,
clinical stage, and adverse 2-year progression-free survival.
In addition, serum ANGPTL4 level in ESCC patients was
much higher than that in patients with benign esophageal
disease (P \ 0.001), and area under the curve was 0.94
(95 % CI 0.886390–0.978173, P \ 0.001). But serum
ANGPTL4 level was significantly decreased at post-oper-
ative 7–10 days (P = 0.004). ANGPTL4 upregulation may
play an important role in ESCC development, and serum
ANGPTL4 level may be a potential tumor marker for
ESCC diagnosis and prognosis.
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Abbreviations
ANGPTL4 Angiopoietin-like protein 4
AUC Area under the curve
ELISA Enzyme-linked immunosorbent assay
ESCC Esophageal squamous cell carcinoma
HCC Hepatocellular carcinoma
HIF-1a Hypoxia-inducible factor 1a
PPARs Proliferators-activated receptors
Background
Esophageal squamous cell carcinoma (ESCC) comprises the
majority of esophageal cancer in China and is characterized
by both high morbidity and high mortality [1]. Although the
disease is surgically curable in its early stages, patients often
suffer asymptomatic metastasis that is associated with a high
mortality [2]. Therefore, it is crucial to develop more
effective screening methods to better predict the course of
the disease. Currently, the most important conventional
prognostic factors are the histological grade and tumor stage
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at the time of diagnosis (pTNM). In addition, molecular
markers such as circulating tumor cells, microRNAs, and
DNA methylation are also employed [3], contributing to
improving the diagnosis, prognosis, and guidance of adju-
vant treatments for ESCC.
Angiopoietin-like protein 4 (ANGPTL4) is a member of
the angiopoietin (ANG) family, which encodes a secretory
glycoprotein highly expressed in adipose tissue, liver,
placental tissue, and ischemic tissues [4]. ANGPTL4 was
previously identified as a paracrine and, possibly, endo-
crine regulator of lipid metabolism and a target of perox-
isome proliferators-activated receptors (PPARs) [5].
Recently, emerging evidence has identified a novel role for
ANGPTL4 in cancer development [6]. Several studies
suggest that ANGPTL4 can prevent metastasis by inhibit-
ing vascular leakiness [7, 8]. Conversely, ANGPTL4 is
also implicated as a pro-angiogenic factor [4], and tumor-
derived ANGPTL4 has been shown to promote metastasis
by disrupting vascular integrity [9]. The explanation of
these conflicting results and the underlying mechanism of
ANGPTL4 activity in tumor cells have not been fully
clarified. Recent reports demonstrate that ANGPTL4
expression is upregulated in the majority of human cancers
including ESCC [6, 10]. As a secreted protein, elevated
levels ANGPTL4 protein have also been detected in the
serum of hepatocellular carcinoma (HCC) and tumor-
bearing mice [11, 12]. Therefore, to explore the precise
role of ANGPTL4 in ESCC pathogenesis, we detected
ANGPTL4 expression levels in tissue and serum samples
from ESCC patients treated with radical resection.
Methods
Study population
This study enrolled 78 ESCC patients who underwent
radical resection without neoadjuvant treatment at Jinling
Hospital from July 2006 to July 2008. All patients under-
went en bloc esophagectomy with locoregional lymphad-
enectomy through a right thoracotomy, laparotomy with
reconstruction using the stomach through a retrosternal
route, and cervical esophagogastrostomy. For patients at
stage IIb or beyond, concurrent or sequential chemora-
diotherapy was administered after surgery.
Patients consisted of 50 males and 28 females, with a
median age of 62 (range 44–83) years. Tumor stage was
conducted according to the 7th edition of the TNM staging
system of the International Union Against Cancer [13], and
patients were at stages I (n = 15), II (n = 25), III
(n = 33), and IV (n = 5, supraclavicular or para-aortic
lymph nodes metastasis). Cellular differentiation was graded
according to the WHO grading system. Ethical approval was
obtained from the hospital, and informed consent was
obtained from all patients prior to sample examination.
Clinical follow-up data were available for all the patients.
For each patient, 5 mL peripheral blood pre-operation and
post-operation (7–10 days) was collected by promoting
coagulation tubes, and then, serum was isolated. Serum
samples from 40 patients with benign esophageal disease
(10 cases of chronic esophagitis, 10 cases of esophageal
leiomyoma, 10 cases of esophageal polyps, and 10 cases of
esophageal achalasia) were also collected.
Immunohistochemical staining
Formalin-fixed, paraffin-embedded samples used for
immunohistochemistry were sectioned at 2 lm thickness.
Sections were deparaffinized using xylene, dehydrated by
gradient ethanol, and then rehydrated with deionized water.
Heat-mediated antigen retrieval was run by autoclave treat-
ment (120 C for 2 min in 1 mmol/L ethylenediaminete-
traacetic acid [EDTA], pH 8.0) and then followed by cooling
at room temperature. Incubation with a polyclonal rabbit
anti-ANGPTL4 antibody (diluted 1:150; R&D Systems,
Minneapolis, Minnesota, USA) was performed overnight at
4 C. After washing with phosphate-buffered saline (PBS),
sections were then incubated with goat anti-rabbit secondary
antibody (Santa Cruz Biotechnology, CA, USA) for 30 min
at room temperature. Coloration was performed with 3,3-
diaminobenzidine. Nuclei were counterstained with hema-
toxylin. PBS was used as a negative control for the staining
reactions. Immunostaining results were evaluated indepen-
dently by 3 pathologists. The percentage of positive cells was
rated as follows: 0 score for 0–5 %, 1 score for 6–25 %, 2
scores for 26–50 %, and 3 scores for more than 50 %. The
staining intensity was rated as follows: 0 score for no stain-
ing, 1 score for weak staining, 2 scores for moderate staining,
and 3 scores for strong staining [14]. The scores from the
percentage and intensity were added to an overall score, and
the expression of the ANGPTL4 protein with an overall score
of 0–2 was designated as ‘low/negative,’ and with an overall
score of 3–6 was designated as ‘high/moderate.’
ANGPTL4 determination in serum
Serum ANGPTL4 levels were determined via enzyme-
linked immunosorbent assay (ELISA) in duplicate, using the
DuoSet ELISA hANGPTL4 kit (R&D Systems, Minneapo-
lis, MN) according to the manufacturer’s instructions. The
serum samples were diluted 1:10 in PBS prior to detection.
Statistical analysis
Statistical tests were carried out using SPSS version 16.0
(SPSS Inc., Chicago, IL, USA). The differences of
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ANGPTL4 expression between the groups were calculated
with Student’s t test. Differences in frequency were
assessed by chi-square test. Overall survival curves were
calculated using the Kaplan–Meier method and compared
by log-rank testing. Multivariate Cox proportional hazard
models were used to define the potential prognostic sig-
nificance of individual parameter. The receiver operating
characteristics (ROC) curve was constructed to describe
diagnostic specificity and sensitivity. P \ 0.05 was taken
as statistically significant.
Results
ANGPTL4 protein expression profiles in ESCC tissue
We detected ANGPTL4 protein expression levels in 78
pairs of ESCC and matched normal tissues by immuno-
histochemical staining. The representative immunohisto-
chemical results are shown in Fig. 1a–d. In total, there
were (delete) 52 cases (69.2 %) showed a higher level of
ANGPTL4 protein expression in tumor tissues than that in
normal tissues, with the average immunostaining scores in
tumor tissues being 3.04 ± 1.80 and 1.42 ± 1.01 in nor-
mal tissues (Fig. 1e, P \ 0.001). Moreover, the rate of
ANGPTL4 protein high/moderate expression in ESCC and
normal tissues was 55.1 % (43/78) and 6.4 % (5/78),
respectively, which showed a significant difference
(P \ 0.001).
Association between ANGPTL4 protein expression
and clinicopathological features
As shown in Table 1, an elevated ANGPTL4 protein
expression in ESCC tissue was significantly associated
with lymph metastasis and clinical stage. However, there
was no correlation between ANGPTL4 protein expression
and patients’ gender, age, tumor site, depth or cellular
differentiation.
Association between ANGPTL4 protein expression
and ESCC prognosis
To the follow-up deadline, there were 39 patients with
progression or relapse within 2 years after the end of sur-
gery. We performed univariate survival analyses to inves-
tigate the possible prognostic role of ANGPTL4 expression
in ESCC. As shown in Fig. 1f, the 2-year progression-free
survival (PFS) in ESCC patients with high/moderate
expression of ANGPTL4 protein was inferior to that with
low/negative expression [mean 16.7 months (95 % CI
14.510–18.839) vs. 20.1 months (95 % CI 18.340–21.946),
P = 0.028].
Furthermore, multiple Cox regression analysis was used
to verify whether the investigated variables including
ANGPTL4 expression were valid predictors of outcome
after adjusting for potential confounding cofactors. Results
showed that high/moderate expression of ANGPTL4 pro-
tein, apart from lymph metastasis, was independent factor
for predicting an adverse 2-year PFS for ESCC patients
(Table 2).
Serum ANGPTL4 levels in pre-/post-operative ESCC
patients
As shown in Fig. 2a, serum ANGPTL4 level in ESCC
patients was significantly higher than that in patients with
benign esophageal disease (202.44 ± 131.03 vs. 63.19 ±
23.06 ng/mL, P \ 0.001). Furthermore, serum ANGPTL4
levels in most ESCC patients were decreased after
7–10 days of surgery, and the pre-/post-operative con-
centrations were 202.44 ± 131.03 ng/mL and 128.73 ±
69.49 ng/mL, respectively (P = 0.004).
We then constructed ROC curve to describe the diag-
nostic specificity and sensitivity of serum ANGPTL4.
Obviously, its detectability to distinguish malignant tumor
is satisfactory, area under the curve (AUC) was 0.94 (95 %
CI 0.886390–0.978173, P \ 0.001), and Youden index was
0.78 (Fig. 2b).
Discussion
Cancer cells do not exist in isolation but rather within a
complex milieu of normal cells, secreted proteins, physi-
ological small molecules, and blood vessels which com-
prise the tumor microenvironment [15]. ANGPTL4 is a
novel secretory glycoprotein which has been reported to
interact with specific extracellular matrix (ECM) proteins
and integrins to facilitate cell migration during wound
healing and cancer development [16, 17]. But the literature
regarding the functions of ANGPTL4 is contradictory.
Both in vitro and in vivo data suggest that ANGPTL4 has
pro-angiogenic effects [4]. ANGPTL4 could stimulate
endothelial cell growth and tubule formation [18], while
the inhibition of ANGPTL4 using siRNAs prevented the
neovascularization process and reduced vascular perme-
ability [19]. Moreover, ANGPTL4 has been reported to
promote tumor growth [20], help tumor cells avoid anoikis
[12, 21], and facilitate tumor cell metastases by interfering
with endothelial cell junctions and induction of vascular
leakiness [9, 22, 23]. Furthermore, clinical studies have
correlated ANGPTL4 expression with venous and lym-
phatic invasion in human gastric and colorectal cancers,
which further emphasized the role of ANGPTL4 in tumor
metastasis [24, 25]. The elevated expression of ANGPTL4
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was also proved to be correlated with poor prognosis in
esophageal and tongue cancers [10, 26]. On the other hand,
several studies showed that increased ANGPTL4 expres-
sion could inhibit tumor growth, metastasis, and angio-
genesis in melanoma, lung, and colorectal cancers [7, 8].
Recently, Okochi-Takada et al. [27] found that ANGPTL4
was a genetically and epigenetically inactivated secreted
tumor suppressor and inhibited tumor angiogenesis in
gastric cancer. These results suggest that the expression
and roles of ANGPTL4 may be tumor-type and microen-
vironment dependent.
In concordance with the results of Shibata et al. [10], we
found that the level of ANGPTL4 protein expression in
ESCC was much higher than that in matched normal tis-
sues, and an elevated expression of ANGPTL4 protein was
significantly associated with lymph metastasis, clinical
stage, and adverse 2-year PFS, further confirming the
important roles of ANGPTL4 dysfunction in ESCC
development in Chinese population.
The expression of ANGPTL4 is considered to be regu-
lated by the nuclear hormone receptors of the PPAR fam-
ily, as well as by hypoxia and chronic inflammatory
pressure. A recent study suggested that prostaglandin E2
(PGE2) may transactivate PPARb/d to regulate the
expression of ANGPTL4 under hypoxic conditions [20].
Because of the aberrant growth of tumor cells and poor
vascularization, the tumor microenvironment tends to
become hypoxic. Several new studies have reported that
hypoxia can induce the expression of ANGPTL4 and that
upregulation of ANGPTL4 is induced by the transcription
factor hypoxia-inducible factor 1a (HIF-1a) [11, 20, 28].
Moreover, the potent regulator of inflammation TGF-b was
Fig. 1 Increased ANGPTL4




9400). a Negative in adjacent
normal esophagus tissues; b low
expression of ANGPTL4 in
tumor; c moderate expression of
ANGPTL4 in tumor; d high
expression of ANGPTL4 in
tumor; e the average
immunostaining scores of
ANGPTL4 expression in tumor
and normal tissues; f 2-year
progression-free survival (PFS)
was analyzed by Kaplan–Meier
survival curve. *P \ 0.05
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found to regulate the expression of ANGPTL4 via a Smad3
signaling pathway [9]. Therefore, we supposed that
upregulation of ANGPTL4 in ESCC was an adaptive
response to tumor microenvironment, which in turn influ-
ence tumor development. For example, this increase in
ANGPTL4 expression enhanced endothelial cell migration
and differentiation, both of which are important processes
in angiogenesis [19], suggesting that it may play a role
in the metastatic processes. Furthermore, studies have
pinpointed ANGPTL4 as a critical mediator in the
transmigration process [12, 22]. TGF-b upregulated
ANGPTL4 in breast tumor cells and then disrupted the
endothelial cell–cell junctions, leading to enhanced vas-
cular leakiness and transendothelial migration of the tumor
cells [9]. ANGPTL4 was found to promote transendothelial
migration and metastasis of HCC cells through the upreg-
ulation of vascular cell adhesion molecule 1 (VCAM-1) on
endothelial cells [11].
In clinical practice, the actual outcome of the patients is
not entirely consistent with the clinicopathological
parameters such as lesion length, invasion depth, and
lymph metastasis, a frequently updated pTNM still fails to
discriminate between degrees of malignancy. One at an
early stage suffers tumor recurrence or metastasis soon
after initial treatment, and others at advanced stages have
long-term survival [29], probably due to the different
molecular biology characteristics of the tumors. Molecular
markers are being sought in ESCC, but few can be applied
in the peripheral blood detection. In the present study, we
found that serum ANGPTL4 level in ESCC patients was
significantly lower than that in patients with benign
esophageal disease, and its diagnostic efficacy was satis-
factory according to AUC curve. Furthermore, serum
ANGPTL4 levels in most ESCC patients were decreased
after 7–10 days after surgery. These results suggested that
serum ANGPTL4 level may be a sensitive tumor bio-
marker for diagnosing or monitoring ESCC.
Previous studies have also shown that serum ANGPTL4
was significantly increased in HCC patients, compared
with chronic hepatitis B patients and normal controls, and
ANGPTL4 levels were significantly higher in HCC patients
with intrahepatic metastasis and macrovascular invasion
than those without [11]. However, the data in colorectal
cancer were diametrically opposed, and Kumara et al. [30]
believe that ANGPTL4 decrease after surgery must be
related to the surgical trauma itself or to the body’s
response to that insult. Thus, serum ANGPTL4 may not be
exclusively secreted by tumor cells, and its application in
clinic needs further study. In our study, whether the serum
ANGPTL4 decrease after ESCC surgery is due to tumor
load reduction, or its raised level in a certain period be
Table 1 Association between ANGPTL4 expression in ESCC tissues
and clinicopathological features
Characteristics No. High/moderate expression
of ANGPTL4 n (%)
P value
Gender
Male 50 29 (58.0) 0.469
Female 28 14 (50.0)
Age
\60 32 15 (46.9) 0.222
C60 46 28 (60.9)
Tumor site
Upper thoracic 15 7 (46.7) 0.646
Middle thoracic 30 16 (53.3)
Lower thoracic 33 20 (60.6)
T status
T1–2 42 20 (47.6) 0.150
T3–4 36 23 (63.9)
Differentiation
Well 14 6 (42.9) 0.322
Moderate 36 23 (63.9)
Poor 28 14 (50.0)
Stage
I/II 40 17 (42.5) 0.021*
III/IV 38 26 (68.4)
Lymph
N0 36 15 (41.7) 0.027*
N1/N2/N3 42 28 (66.7)
* P \ 0.05
Table 2 Multivariate analysis
of clinicopathological factors
for 2-year progression-free
survival (PFS) of 78 patients
with ESCC
* P \ 0.05
Characteristics Category RR (95 % CI) P value
Age C60 versus \60 years 1.523 (0.603–3.812) 0.389
Tumor differentiation Poor versus well/moderate 1.656 (0.611–4.109) 0.305
T status T3–4 versus T1–2 1.751 (0.784–3.921) 0.172
Lesion length C5 cm versus \5 cm 1.172 (0.435–3.156) 0.652
Lymph metastasis N1/N2/N3 versus N0 2.845 (1.132–7.212) 0.025*
ANGPTL4 expression in tissue High/moderate versus low/negative 2.594 (1.016–6.568) 0.034*
KPS scores C90 versus \90 0.585 (0.223–1.620) 0.423
Med Oncol (2013) 30:680 Page 5 of 7
123
related to tumor recurrence or progression should be vali-
dated by long-term follow-up data in the future.
Conclusions
We confirmed that ANGPTL4 upregulation plays impor-
tant roles in ESCC development, and serum ANGPTL4
level may be a potential tumor marker for ESCC diagnosis
and prognosis.
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